Helperby has discovered and is developing a suite of Antibiotic Resistance Breakers (ARBs). These compounds, when combined with old antibiotics, can restore the original potency against both Gram positive and Gram negative bacteria. One of these combinations (ARB-002) is active against all three of the critical priority pathogens identified by the World Health Organisation.*
Helperby’s ARBs have unique mechanisms of action and differ from other antibiotics in clinical use. They are highly relevant to major commercially valuable markets & are covered internationally by extensive patents.
Two of Helperby’s ARBs are currently in development in six pre-clinical and clinical trials:
* Antibacterial Agents in Clinical Development, WHO 2017
All new antibiotics face the threat of resistance from increasingly smart bacteria. Using Helperby’s ARBs, it may be possible to renew old antibiotics over and over again for hundreds of years, rather like renewable energy:
View the Helperby Therapeutics product pipeline